Clinical data and circulating t(14;18)-positive cells before and after induction treatment (patients numbered according to numbers of t(14;18)-positive cells before induction)
| Patient . | Stage . | Bone marrow . | Bulky disease . | Response to induction . | t(14;18) Lymph node . | t(14;18) Before induction3-150 . | t(14;18) After induction3-150 . |
|---|---|---|---|---|---|---|---|
| 1 | IV3-152 | + | − | PR | + | 76 145 | 1 |
| 23-151 | IV3-152 | + | − | PR | + | 31 890 | 3 |
| 3 | IV | + | + | PD | + | 8 573 | ND |
| 4 | IV | + | + | PD | + | 2 467 | ND |
| 5 | IV | + | + | PD | + | 2 217 | 10 |
| 6 | IV | + | − | PR | + | 1 779 | 1 |
| 7 | III | − | − | CR | + | 1 706 | 12 |
| 8 | IV | + | − | CR | ND | 1 684 | ND |
| 93-151 | IV | + | + | PR | + | 1 657 | 361 |
| 10 | IV | + | − | CR | + | 1 410 | ND |
| 11 | IV | + | − | CR | + | 1 234 | 0 |
| 12 | IV | + | + | PR | + | 991 | 79 |
| 13 | IV | + | − | CR | + | 436 | 1 |
| 14 | IV | + | − | CR | + | 351 | 1 |
| 15 | IV | + | − | PR | + | 319 | 0 |
| 16 | III | ND | − | CR | ND | 311 | 0 |
| 17 | IV | + | − | PR | + | 277 | 177 |
| 18 | IV | + | − | CR | + | 247 | 0 |
| 19 | II | − | + | SD | ND | 80 | 11 |
| 20 | IV | + | + | CR | ND | 71 | 0 |
| 21 | III | ND | + | PR | + | 70 | 0 |
| 22 | II | − | + | CR | + | 63 | 0 |
| 23 | III | − | + | CR | + | 34 | 0 |
| 243-151 | III | − | + | CR | + | 25 | 5 |
| 25 | II | − | + | PD | − | 24 | 1 |
| 26 | IV | + | − | CR | + | 16 | 0 |
| 27 | IV | + | + | SD | + | 16 | 1 |
| 283-151 | III | − | − | CR | − | 10 | ND |
| 29 | IV | + | − | CR | + | 7 | ND |
| 303-151 | IV | + | + | PR | − | 3 | 0 |
| 313-151 | III | − | + | PD | + | 2 | 0 |
| 32 | III | − | + | CR | − | 1 | 0 |
| 333-151 | IV | + | − | PR | + | 1 | 0 |
| 34 | IV | + | + | PR | − | 1 | 406 |
| Patient . | Stage . | Bone marrow . | Bulky disease . | Response to induction . | t(14;18) Lymph node . | t(14;18) Before induction3-150 . | t(14;18) After induction3-150 . |
|---|---|---|---|---|---|---|---|
| 1 | IV3-152 | + | − | PR | + | 76 145 | 1 |
| 23-151 | IV3-152 | + | − | PR | + | 31 890 | 3 |
| 3 | IV | + | + | PD | + | 8 573 | ND |
| 4 | IV | + | + | PD | + | 2 467 | ND |
| 5 | IV | + | + | PD | + | 2 217 | 10 |
| 6 | IV | + | − | PR | + | 1 779 | 1 |
| 7 | III | − | − | CR | + | 1 706 | 12 |
| 8 | IV | + | − | CR | ND | 1 684 | ND |
| 93-151 | IV | + | + | PR | + | 1 657 | 361 |
| 10 | IV | + | − | CR | + | 1 410 | ND |
| 11 | IV | + | − | CR | + | 1 234 | 0 |
| 12 | IV | + | + | PR | + | 991 | 79 |
| 13 | IV | + | − | CR | + | 436 | 1 |
| 14 | IV | + | − | CR | + | 351 | 1 |
| 15 | IV | + | − | PR | + | 319 | 0 |
| 16 | III | ND | − | CR | ND | 311 | 0 |
| 17 | IV | + | − | PR | + | 277 | 177 |
| 18 | IV | + | − | CR | + | 247 | 0 |
| 19 | II | − | + | SD | ND | 80 | 11 |
| 20 | IV | + | + | CR | ND | 71 | 0 |
| 21 | III | ND | + | PR | + | 70 | 0 |
| 22 | II | − | + | CR | + | 63 | 0 |
| 23 | III | − | + | CR | + | 34 | 0 |
| 243-151 | III | − | + | CR | + | 25 | 5 |
| 25 | II | − | + | PD | − | 24 | 1 |
| 26 | IV | + | − | CR | + | 16 | 0 |
| 27 | IV | + | + | SD | + | 16 | 1 |
| 283-151 | III | − | − | CR | − | 10 | ND |
| 29 | IV | + | − | CR | + | 7 | ND |
| 303-151 | IV | + | + | PR | − | 3 | 0 |
| 313-151 | III | − | + | PD | + | 2 | 0 |
| 32 | III | − | + | CR | − | 1 | 0 |
| 333-151 | IV | + | − | PR | + | 1 | 0 |
| 34 | IV | + | + | PR | − | 1 | 406 |
ND indicates not done; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; t(14;18) lymph node +, present (analyzed by conventional PCR in patients 1-31 and 33 and by karyotyping in patient 32); t(14;18) lymph node −, absent; t(14;18) lymph node ND, not done; t(14;18) blood, number of circulating t(14;18)-positive cells per 75 000 cells.
Number of circulating t(14;18)-positive cells per 75 000 cells.
Previous wait-and-see policy.
Leukemic.